Publications by authors named "Barbara Coffey"
Naltrexone Treatment for Multiple Substance Use Disorders in an Adolescent Boy.
J Child Adolesc Psychopharmacol
October 2024
Objective: To provide an overview of Joe Biederman's contributions to child and adolescent psychiatry.
Method: Nine colleagues described his contributions to: psychopharmacology, comorbidity and genetics, pediatric bipolar disorder, autism spectrum disorders, Tourette's and tic disorders, clinical and neuro biomarkers for pediatric mood disorders, executive functioning, and adult ADHD.
Results: Joe Biederman left us with many concrete indicators of his contributions to child and adolescent psychiatry.
Understanding and Managing New Onset Homicidal Ideation in an Adolescent with Depression.
J Child Adolesc Psychopharmacol
November 2023
Background: Tourette syndrome (TS) is a neurodevelopmental disorder characterized by motor and phonic tics.
Objective: To assess the safety and efficacy of deutetrabenazine (Teva Neuroscience, Inc, Parsippany, NJ), a vesicular monoamine transporter 2 inhibitor, in children and adolescents with TS.
Methods: Alternatives for Reducing Tics in TS (ARTISTS) open-label extension (OLE) (NCT03567291) was a 54-week, global, phase 3, open-label extension study of deutetrabenazine (6-48 mg daily) conducted May 28, 2018 to April 3, 2020 with a 2-week randomized withdrawal period.
Cannibalistic Ideation in a 14-Year-Old Girl: Psychosis or Trauma?
J Child Adolesc Psychopharmacol
August 2023
Clonazepam Treatment of Adolescent Catatonia in A Setting of Lorazepam-Related Hypotension.
J Child Adolesc Psychopharmacol
February 2023
Clozapine and Constipation: Considerations in an Obese Adolescent Girl.
J Child Adolesc Psychopharmacol
December 2022
Over the past 3 years, a global phenomenon has emerged characterized by the sudden onset and frequently rapid escalation of tics and tic-like movements and phonations. These symptoms have occurred not only in youth known to have tics or Tourette syndrome (TS), but also, and more notably, in youth with no prior history of tics. The Tourette Association of America (TAA) convened an international, multidisciplinary working group to better understand this apparent presentation of functional neurological disorder (FND) and its relationship to TS.
View Article and Find Full Text PDFPharmacologic Treatment of Comorbid Attention-Deficit/Hyperactivity Disorder and Tourette and Tic Disorders.
Child Adolesc Psychiatr Clin N Am
July 2022
A complete and comprehensive medical and psychiatric evaluation is necessary to delineate tic symptoms from attention-deficit/hyperactivity disorder, and to prioritize the most problematic symptoms for intervention. Stimulants are the recommended first-line pharmacotherapy to treat attention-deficit/hyperactivity disorder symptoms in patients with tic disorders. Comprehensive behavioral intervention for tics is an effective behavioral therapy that is generally considered the first-line treatment of persistent tic disorders.
View Article and Find Full Text PDFEditorial: Persistent Tics, Behavior Therapy, and the Tincture of Time.
J Am Acad Child Adolesc Psychiatry
June 2022
Fluoxetine-Induced Serum Sickness-Like Reaction in an Adolescent with Obsessive Compulsive Disorder and Diabetes.
J Child Adolesc Psychopharmacol
November 2021
Article Synopsis
- Tourette syndrome is a neurodevelopmental disorder that leads to the development of motor and phonic tics, and this study focuses on testing deutetrabenazine, a drug previously approved for other conditions, to see if it can help manage these tics.
- The ARTISTS 2 study recruited children and adolescents aged 6 to 16 with Tourette syndrome, with participants randomly assigned to receive either low-dose, high-dose deutetrabenazine, or a placebo over an 8-week period.
- The main measure of effectiveness was the change in tic severity, assessed using the Yale Global Tic Severity Scale, while safety was evaluated through monitoring side effects and other health metrics.